Kindred Biosciences Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Kindred Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View analyst ratings for Kindred Biosciences or view top-rated stocks.

Wall Street analysts have given Kindred Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Kindred Biosciences.

Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.24). The biopharmaceutical company earned $2.40 million during the quarter, compared to the consensus estimate of $4.60 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 8.50% and a negative net margin of 19.96%.
View Kindred Biosciences' earnings history.

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KIN shares have increased by 13.8% and is now trading at $9.21.
View which stocks have been most impacted by COVID-19.

5 brokerages have issued twelve-month price targets for Kindred Biosciences' stock. Their forecasts range from $9.25 to $15.25. On average, they expect Kindred Biosciences' share price to reach $10.80 in the next year. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for Kindred Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Kindred Biosciences include Aurinia Pharmaceuticals (AUPH), Constellation Pharmaceuticals (CNST), Heron Therapeutics (HRTX), Indivior (INVVY), ADC Therapeutics (ADCT), uniQure (QURE), Prelude Therapeutics (PRLD), Cytokinetics (CYTK), Y-mAbs Therapeutics (YMAB), PMV Pharmaceuticals (PMVP), Design Therapeutics (DSGN), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), PureTech Health (PRTC) and Kura Oncology (KURA).
View all of KIN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Park West Asset Management LLC (14.17%), Point72 Asset Management L.P. (8.50%), BlackRock Inc. (6.00%), Ameriprise Financial Inc. (4.42%), Renaissance Technologies LLC (3.13%) and Dimensional Fund Advisors LP (2.60%). Company insiders that own Kindred Biosciences stock include Denise Bevers and Park West Asset Management Llc.
View institutional ownership trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Renaissance Technologies LLC, Morgan Stanley, Millennium Management LLC, Northern Trust Corp, General American Investors Co. Inc., Dimensional Fund Advisors LP, and The Manufacturers Life Insurance Company. Company insiders that have sold Kindred Biosciences company stock in the last year include Denise Bevers, and Park West Asset Management Llc.
View insider buying and selling activity for Kindred Biosciences or view top insider-selling stocks.

KIN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granite Point Capital Management L.P., Acadian Asset Management LLC, DCF Advisers LLC, Squarepoint Ops LLC, Allianz Asset Management GmbH, Geode Capital Management LLC, and QS Investors LLC.
View insider buying and selling activity for Kindred Biosciences or or view top insider-buying stocks.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KIN stock can currently be purchased for approximately $9.21.

Kindred Biosciences has a market capitalization of $416.97 million and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Kindred Biosciences employs 63 workers across the globe.

The official website for Kindred Biosciences is kindredbio.com.

Kindred Biosciences is headquartered at 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]